Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:20:49 2024-07-18 EDT			5-day change	1st Jan Change
97.61 ^CHF	-1.46%		-1.74%	+14.94%

12:21pm	Novartis Lifts Full-Year Guidance on 'Strong Momentum' of Key Growth Drivers	MT
11:34am	European Midday Briefing : Tech Steadies as Focus Turns to ECB	DJ

NOVARTIS AG : Goldman Sachs maintains a Buy rating

July 18, 2024 at 04:35 am

James Quigley from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at CHF 106.

Latest news about Novartis AG

Novartis Lifts Full-Year Guidance on 'Strong Momentum' of Key Growth Drivers	06:21am	MT
European Midday Briefing : Tech Steadies as Focus Turns to ECB	05:34am	DJ
NOVARTIS AG : Goldman Sachs maintains a Buy rating	04:35am	ZD
NOVARTIS AG : Buy rating from Jefferies	04:03am	ZD
Novartis raises profit target for 2024	03:14am	CF
Novartis Raises Profit Guidance as Key Drugs Boost Sales -- Update	01:59am	DJ
Novartis Raises Profit Guidance as Key Drugs Boost Sales	01:44am	DJ
Novartis Reports Higher H1 Attributable Net Income, Net Sales	01:28am	MT
Novartis raises 2024 profit guidance for second time	01:16am	RE
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance	01:00am	DJ
Novartis AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	10:21pm	CI
Brace for a flurry of speeches from Fed officials	07-15
European companies cut jobs as economy sputters	07-15	RE
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	07-15	MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings	07-12	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	07-12	MT
Global markets live: KKR, Apple, Tesla, Oracle, McDonald's...	07-12
Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected	07-11	MT
Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected	07-11	MT
Markets Powered by Alternating Current	07-10
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	07-10	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	07-10	MT
European companies cut jobs as economy sputters	07-09	RE
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief	07-08	MT
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	07-05	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

01:00am - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.9 USD

Average target price

112.7 USD

Spread / Average Target

+0.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+15.03%	228B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.50%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.27%	247B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B
SANOFI	+2.91%	126B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Goldman Sachs maintains a Buy rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals